A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
A phase 2 trial of Ciltacabtagene autoleucel, Cyclophosphamide, Fludarabine in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel is a phase 2 interventional study registered as NCT07149857 by Janssen Research & Development, LLC, with 60 participants planned, started 2025-10-03 and due to reach its primary completion in 2028-04-12. Interventions recorded: Cilta-cel, Cyclophosphamide, Induction therapy, Fludarabine. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Shares Ciltacabtagene autoleucel, Johnson & Johnson, Multiple myeloma.
- TrialBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Shares Fludarabine, Cyclophosphamide.